Get started
Author

Dorothee E. Schliephake

Observed names: D E Schliephake, D Schliephake, D. Schliephake, Dorothee Schliephake, Schliephake, Dorothee
OpenAlex ID: A5006986458
Efficacy and Safety of Great Saphenous Vein Sclerotherapy Using Standardised Polidocanol Foam (ESAF): A Randomised Controlled Multicentre Clinical Trial
2007 · E. Rabe, J. Otto, et al. · European Journal of Vascular and Endovascular Surgery · 174
PDF
Blimp‐1 overcomes the block in IgM secretion in lipopolysaccharide / anti‐μ F(ab′)2‐co‐stimulated B lymphocytes
1996 · Dorothee E. Schliephake, Anneliese Schimpl · European Journal of Immunology · 88
Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study)
2010 · E Rabe, D Schliephake, et al. · Phlebology The Journal of Venous Disease · 85
The French Polidocanol Study on Long-Term Side Effects
2010 · Jean Jerome Guex, Dorothee E. Schliephake, et al. · Dermatologic Surgery · 41
Concept for a study design in patients with severe community-acquired pneumonia: A randomised controlled trial with a novel IGM-enriched immunoglobulin preparation – The CIGMA study
2015 · Tobias Welte, R. Phillip Dellinger, et al. · Respiratory Medicine · 35
PDF
Efficacy and safety of Aethoxysklerol® (polidocanol) 0.5%, 1% and 3% in comparison with placebo solution for the treatment of varicose veins of the lower extremities in Chinese patients (ESA-China Study)
2011 · J Zhang, Z Jing, et al. · Phlebology The Journal of Venous Disease · 31
A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects
2017 · Willem Hettema, Christopher Wynne, et al. · Expert Opinion on Investigational Drugs · 29
PDF
Phase 3 Trial of BI 695502 Plus Chemotherapy Versus Bevacizumab Reference Product Plus Chemotherapy in Patients With Advanced Nonsquamous NSCLC
2021 · Edward S. Kim, Sigrid Balser, et al. · JTO Clinical and Research Reports · 10
PDF
Effektivität der Sklerosierungstherapie in Abhängigkeit vom Alter der Patienten
2010 · K. Denk, D. Schliephake, et al. · Phlebologie · 3
Phase IIIb study of the bevacizumab biosimilar candidate BI 695502 plus mFOLFOX6 in metastatic colorectal cancer
2022 · Tanios S Bekaii-Saab, Sigrid Balser, et al. · Colorectal Cancer · 1
Works count: 11
Citation count: 497
H-index: 8
I10-index: 8
Year
Topic
Type